GH001 is our proprietary inhalable 5-MeO-DMT product candidate.
We have completed a Phase 1 healthy volunteer clinical trial, in which administration of GH001 via inhalation was observed to be well tolerated at the investigated single dose levels and in an individualized dosing regimen with intra-subject dose escalation within a single day.
GH001 is currently being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with Treatment-Resistant Depression.
GH002 is our 5-MeO-DMT product candidate formulated for administration via a proprietary injectable approach. GH002 is currently in preclinical development and we anticipate developing GH002 in indications within our focus area of psychiatric and neurological disorders.